Starr Ephraim purchased $8K of AZTA

Starr Ephraim (SVP, Gen Counsel & Secretary) purchased 335 shares of Azenta, Inc. (AZTA) at $24.17 on 2026-07-31.

Original reporting
SEC EDGAR · Starr Ephraim
Published Aug 4, 2026, 10:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 4, 2026, 10:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AZTA
Neutral
medium confidence
Mentioned
$AZTA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AZTANeutralLow
01

Why it matters

A single officer open-market purchase is disclosed, but the filing contains no new operational or financial information about Azenta.

02

Market read

Traders may note the insider buy as mild sentiment input, but there is no fundamental catalyst in the text.

03

What to watch

The filing does not state intent, timing rationale, or whether the purchase was part of a broader pattern; the absence of a 10b5-1 plan does not confirm conviction.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-04, transaction dated 2026-07-31

Background

The article is an SEC Form 4 insider transaction disclosure for Azenta, Inc.

Company-level read

Ticker impact

$AZTANeutralMedium confidence
Context

Azenta disclosed a Form 4 showing SVP General Counsel Starr Ephraim bought 335 shares of AZTA at $24.1676 on 2026-07-31.

Expected impact

Likely limited near-term impact; any effect is sentiment-only unless paired with other company-specific news.

Evidence & confidence

Form 4 insider buys can be informative, but the article provides no accompanying guidance, contract, investigation, or operational change. The transaction size ($8.1k) is small relative to typical market-moving thresholds.

Market effects

No clear sector read-through from a small insider open-market buy.

None indicated.

None indicated.

Counterpoint

Insider buys can be driven by personal liquidity needs or diversification rather than a bullish view, especially without a clear linkage to company events.

Key entities

  • Azenta, Inc.

    Company subject of the Form 4 insider transaction disclosure.

  • Starr Ephraim

    SVP, General Counsel & Secretary who purchased AZTA shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AZTAHigh

Why Azenta Stock Crushed it on Wednesday

Azenta (AZTA) stock surged 21% after reporting Q4 2026 revenue of $167M, up 5% YoY, and adjusted earnings of $0.28 per share, exceeding estimates. The company guided FY2027 revenue to $648M-$660M with margin expansion. Azenta focuses on automated sample storage for healthcare.

$AZTAHigh

Azenta (AZTA) Q4 2026 Earnings Call Transcript

Azenta (AZTA) reported Q4 2026 revenue slightly better than expected, with double-digit growth in Sample Repository Services and Consumables & Instruments. The company aims for profitable revenue growth in 2027, with initiatives in commercial expansion and new product launches. Fiscal 2026 saw 2% organic revenue growth and an adjusted EBITDA margin of 9.4%.

$AZTAMedAI 8/10

What Azenta (AZTA) Said on Its Q4 Earnings Call

Azenta (AZTA) reported Q4 revenue growth of 9% in Sample Management Solutions and flat revenue in Multiomics. The company expects 3-4% organic revenue growth in Q1 and improved free cash flow by 25% in fiscal 2026. Automated Stores faced challenges but is expected to return to modest growth. Azenta made acquisitions in gene synthesis and plans restructuring for cost savings.